Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lingdolinurad extension study in gout
NCT06276556Phase 3Terminated
- Sponsor
- Atom Therapeutics
- Start
- Apr 2024
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 3 trial of lingdolinurad in gout, sponsored by Atom Therapeutics. Started Apr 2024; status: terminated.
02
Drugs
lingdolinurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT06276556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06276556.